Skip to main content
. 2015 Feb 8;8:10. doi: 10.1186/s13045-014-0105-1

Figure 6.

Figure 6

IGFBP7 promotes osteogenesis and is associated with myeloma bone disease. (A) Primary BMSCs were cultured in osteogenic medium for 21 days. IGFBP7 expression was analysed during osteogenesis by quantitative PCR at the indicated time points. The graph represents the relative expression compared to day 0 of osteogenesis. (B) Alkaline phosphatase activity in primary BMSCs was determined at days 7 and 14 of differentiation in the presence or absence of rhIGFBP7 (1 or 10 μg/ml) and is displayed relative to the control (PBS/BSA 0.1%). For neutralization experiments, alkaline phosphatase activity in primary human BMSCs (C) and BMSC TERT+ cells (D) was analysed at day 14 of osteogenesis in the presence of activin A (50 or 100 ng/ml) and/or rhIGFBP7 (10 μg/ml). Results are displayed relative to the control (PBS/BSA 0.1%). (A-D) Values represent the mean ± SD of three independent experiments performed in triplicates. (E) IGFBP7 expression was analysed with regard to the severity of myeloma bone disease. Grey data points indicate an absent, black data points a present Affymetrix detection call. Asterisks indicate statistical significance compared with the control (* P < 0.05, ** P < 0.01, *** P < 0.001).